Literature DB >> 2813776

Invasive pulmonary aspergillosis: evaluation with MR imaging.

C J Herold1, J Kramer, K Sertl, P Kalhs, R Mallek, H Imhof, D Tscholakoff.   

Abstract

Eleven patients with suspected invasive pulmonary aspergillosis underwent magnetic resonance (MR) imaging. Images were obtained with standard spin-echo sequences and electrocardiographic triggering before and after intravenous administration of gadolinium diethylenetriaminepentaacetic acid. Thirty-seven of 48 lesions seen on MR images were nodular infiltrates; 34 of these had a targetlike appearance, with hypointense centers and iso- or hyperintense rims. Twenty-three of 37 nodular lesions contained areas of hyperintensity on T1-weighted images. All 37 had enhanced rims on postcontrast MR images. The remaining 11 lesions were segmental infiltrates, seven of which were predominantly hyperintense on T1-weighted images. In one patient with nodular lesions, MR imaging findings were correlated with those from pathologic analysis of a resected upper lobe. Areas of hyperintensity corresponded to subacute hemorrhage permeated by Aspergillus organisms. The authors believe that the typical targetlike appearance of nodular lesions on MR images and the potential that MR imaging has to reveal hemorrhagic content will prove useful in the early diagnosis of invasive pulmonary aspergillosis.

Entities:  

Mesh:

Year:  1989        PMID: 2813776     DOI: 10.1148/radiology.173.3.2813776

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Spinal epidural aspergillosis in a patient with HIV resulting from long-standing (3 years) lung infection.

Authors:  R D Murtagh; M J D Post; J Bruce; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

2.  Pulmonary MRI--a new approach for the evaluation of febrile neutropenic patients with malignancies.

Authors:  C Rieger; P Herzog; R Eibel; M Fiegl; H Ostermann
Journal:  Support Care Cancer       Date:  2007-10-18       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.